Subscribe To
Context therapeutics has 39.4m cash runway to advance pipeline programs; data update from oath phase 2 trial likely in mid-2023
Context Therapeutics (NASDAQ:CNTX) Inc has indicated in its corporate guidance for 2023 that with ample cash on hand, the company has the scope to a...
January 4, 2023, 9:41 am
Catalent, inc. to present at the 41st annual j.p. morgan healthcare conference
SOMERSET, N.J.--( BUSINESS WIRE )--Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimiz...
January 3, 2023, 5:15 pm
Opus genetics announces acquisition of the rights to two gene therapy product candidates for inherited retinal diseases
Opus to advance preclinical development programs for BEST1– and RHO-related retinal diseases Deal expands Opus’ addressable patient population for...
December 28, 2022, 1:00 pm
4 top biotech stocks worth adding to your portfolio in 2023
New drug approvals and focus on coronavirus treatments should maintain momentum for the Zacks Biomedica...
December 27, 2022, 12:47 pm
Hims & hers health: the ultimate pick for 2023
Hims & Hers Health is a telehealth company which solves two major issues for patients in modern healthcare: it provides easier access to physicians an...
December 23, 2022, 3:52 pm
Poolbeg pharma identifies possible new rsv treatments as infection rates soar
Poolbeg Pharma said it had identified five potential new drug candidates from its Respiratory Syncytial Virus (RSV) AI collaboration with One Three B...
December 21, 2022, 2:32 am
Intellia: in-vivo gene editing platform continues to deliver
In-vivo CRISPR/Cas9 knock out gene editing treatments NTLA-2002 and NTLA-2001 have established proof of...
December 20, 2022, 8:25 am
Madrigal’s stock rallies about 200% after sharing positive data about its nash treatment candidate
Shares of Madrigal Pharmaceuticals Inc. soared 209.6% in premarket trading on Monday after the company shared positive data from a pivotal Phase 3 cli...
December 19, 2022, 1:07 pm
Will intellia therapeutics stock rebound after a 31% fall in a month?
Intellia Therapeutic's stock (NASDAQ: NTLA), a biotechnology company developing treatments using the CR...
December 19, 2022, 8:00 am
Lilly, sosei to develop new treatments for diabetes and metabolic diseases
Eli Lilly & Co. Inc. and Sosei Group Corp. said Friday they plan to develop and commercialize therapies for diabetes and metabolic diseases. Lilly is ...
December 16, 2022, 7:50 am
Nuvalent looks overvalued after a rapid rally
Surprisingly, Nuvalent, Inc. has attracted a lot of market interest over the past year, while known headwinds have put the entire biotech sector under...
December 14, 2022, 3:48 pm
Amgen continues trailblazing with $26 billion horizon acquisition
Biotech giant Amgen Inc. ( AMGN , Financial) is on a mission to meet unmet medical needs while generating solid returns for investors. As part of this...
December 13, 2022, 6:14 pm
Eli lilly sets guidance for 2023 and stock falls as eps lags current consensus
Eli Lilly & Co. LLY, +1.73% announced guidance for 2023 on Tuesday and highlighted potential launches for a series of ...
December 13, 2022, 6:54 am
Numinus to participate in the kcsa mental health virtual investor conference on december 15, 2022
VANCOUVER, BC , Dec. 12, 2022 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care com...
December 12, 2022, 4:10 pm
Amgen to buy horizon therapeutics for $116.50 per share
Amgen will acquire Horizon Therapeutics, a biopharmaceutical company that focuses on treatments for rar...
December 12, 2022, 8:11 am
Entrada therapeutics shares jump on collaboration with vertex
Shares of Entrada Therapeutics Inc. TRDA, +3.20% rallied 15% in premarket trading on Thursday after the company announced a deal with Vertex Pharmaceu...
December 8, 2022, 8:24 am
Eiger biopharmaceuticals to host conference call to discuss phase 3 d-livr study results of lonafarnib-based treatments in hepatitis delta virus (hdv) on thursday, december 8, 2022
Live Conference Call and Webcast at 8:30 AM ET PALO ALTO, Calif. , Dec. 7, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a comm...
December 7, 2022, 4:05 pm
3 biotech stocks aiming to reinvent mental health treatment
Atai, Biogen, and Sage are working to develop new treatments for mental illness....
December 6, 2022, 9:49 pm
Poseida therapeutics to present early data from phase 1 trials of p-muc1c-allo1 and p-bcma-allo1 at esmo immuno-oncology 2022 annual congress
P-MUC1C-ALLO1 and P-BCMA-ALLO1 were well tolerated, with no dose-limiting toxicities (DLTs), cytokine release syndrome (CRS), graft vs host disease (G...
December 6, 2022, 6:00 am
Respirerx pharmaceuticals inc. enters a collaboration with national institute for neurological disorders and stroke to advance its lead gabakine toward clinical development
Glen Rock, N.J., Dec. 05, 2022 (GLOBE NEWSWIRE) — RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) (“RespireRx” or the “Company”), a leade...
December 5, 2022, 1:30 pm